The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma
- PMID: 36841693
- DOI: 10.1016/j.ejso.2023.02.009
The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma
Abstract
Objective: To evaluate the prognostic value of tumor budding and tumor-stroma ratio (TSR) in resected pulmonary metastases of colorectal carcinoma (CRC).
Methods: In total, 106 pulmonary metastasectomies were performed to 74 patients in two study hospitals during 2000-2020. All relevant clinical data were retrospectively collected. Tumor budding based on the International Tumor Budding Consensus Conference recommendations and TSR in the first resected pulmonary metastases and primary tumors were evaluated from diagnostic hematoxylin-eosin-stained histopathological slides.
Results: 60 patients (85.7%) had low tumor budding (≤5 buds/field) and 10 patients (14.3%) had high tumor budding (>5 buds/field) in their first pulmonary metastases of CRC. 5-year overall survival rates of pulmonary metastasectomy in low and high total tumor budding were 28.3% and 37.3% (p = 0.387), respectively. 19 patients (27.1%) had low TSR and 51 patients (72.9%) had high TSR. The 5-year overall survival rates were 32.9% in low and 28.6% in high TSR of first pulmonary metastases (p = 0.746). Tumor budding and TSR did not provide prognostic value in Cox multivariate analysis. Tumor budding and TSR in resected pulmonary metastases were not associated with those of the primary tumor.
Conclusion: Tumor budding and TSR in the resected pulmonary metastases of CRC showed no statistically significant prognostic value, however, additional well-powered confirmatory studies are needed.
Keywords: Colorectal cancer; Pulmonary metastases; Tumor budding; Tumor-stroma ratio.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: T.T.S. reports consultation fees from Boehringer Ingelheim Finland and Amgen Finland and being a co-owner and CEA of Healthfund Finland.
Comment on
-
Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.Mod Pathol. 2017 Sep;30(9):1299-1311. doi: 10.1038/modpathol.2017.46. Epub 2017 May 26. Mod Pathol. 2017. PMID: 28548122 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
